characterized by periodic inflammation in the absence of infection, autoantibodies or self-reactive lymphocytes. Therefore, AIS has defining characteristics that differ from those of autoimmune diseases. The sterile inflammation observed in AIS is likely caused by the dysregulation of the innate immune system. However, the etiologies and physiopathologies of these autoinflammatory disorders remain ambiguous. Uncontrolled interleukin (IL)-1 biosynthesis, which is initiated by danger signals in the inflammasome or via nucleic acid-sensing pathways, has been suggested to have a critical role in AISs such as Behçet's disease, Familial Mediterranean fever and Cryopyrin-associated periodic syndrome. In addition, other proinflammatory cytokines, including TNF-α, Type-I interferons and IL-18, have been implicated in organ-specific inflammation in AISs. In clinical studies, colchicine and anti-TNF-α mAb have been used to treat AIS patients, and IL-1 blockade therapies (treatment with IL-1R inhibitor or anti-IL-1β mAb) significantly reduced disease progression and induced sustained remission in a substantial number of patients. 1 Unfortunately, some patients still have poor responses to these therapies, and their diseases progress with multi-organ inflammation. Thus, scientists continue to search for new strategies with higher efficiency for AIS patients.
Neutrophilic dermatoses, including Sweet's syndrome, pyoderma gangrenosum and subcorneal pustular dermatosis, are a group of inherited AISs that present with excessive neutrophil infiltration in the skin lesions. In past years, the mutation of Ptpn6 gene, which encodes a phosphatase PTPN6 (protein tyrosine phosphatase nonreceptor type 6) or SHP-1 (Src homology region 2 (SH2) domain-containing protein phosphatase), has been linked to not only neutrophilic dermatoses but also autoimmune diseases and hematological malignancies in humans. 2 In mice, several Ptpn6 mutants have been identified and characterized. A loss of PTPN6 in mice (motheaten, Ptpn6 me/me ) results in severe systemic inflammation and death by 3 to 4 weeks of age. Compared to Ptpn6 me/me mice, Ptpn6 me-v/me-v (motheaten-viable, a T-to-A transversion at a splice consensus site) mice also develop myeloproliferative disease but die at~9 to 10 weeks of age. However, Ptpn6 meb2/meb2 (insertion of a B2 element into exon 6) mice present with autoinflammatory diseases, but their life span could be prolonged to 6 to 8 months. Interestingly, hypomorphic Ptpn6 spin (spontaneous inflammation, with a Y208N missense mutation in the carboxy terminus) mice can survive for 1 year and display symptoms that resemble those of neutrophilic dermatoses in human. 3 Therefore, additional genetic and functional studies of PTPN6 have been facilitated by using these viable mice.
Previous studies have shown that the cutaneous inflammation in PTPN6-deficient mice is driven by neutrophils. 4 The Kanneganti group at St. Jude Children's Research Hospital has a series of publications that explore this autoinflammatory skin disease using mouse models. They reported that Ptpn6 Spin Il1a − / − mice, but not Ptpn6 Spin Il1b − / − mice, ablate the symptoms of dermatoses. 5 Their findings suggest an unknown regulation of the IL-1α pathway that is involved in inflammatory skin disease. In a recent study, 6 the Kanneganti group further dissected the innate immune factors that may be correlated to the disease incidence using genetic tools and ruled out the requirement of TLRs, TRIF, NODs, RIPK2, type-I IFN, STING, integrin-signaling axes and caspase-1/-8 for inflammatory skin disease. In addition, a bone marrow transfer study revealed that IL-1α is synthesized by the radioresistant (nonhematopoietic) cells but that IL-1R is necessary in both radioresistant and hematopoietic cells for disease progression. Moreover, they demonstrated that the expression of myeloid differentiation primary response gene 88 (MyD88), receptor interacting protein kinase 1 (RIPK1), tumor growth factor-β activated kinase 1 (TAK1) and spleen tyrosine kinase (Syk) in myeloid cellspecific IL-1R signaling is critical to provoke inflammatory skin disease in Ptpn6 spin mice. Furthermore, the phosphorylation of MyD88 by Syk is essential to activate IL-1R downstream signaling. Thus, they concluded that the main function of PTPN6 is to inhibit Sykdependent MyD88 phosphorylation by inactivating Syk, which prevents IL-1α-mediated autoinflammation in the skin (Figure 1 ).
IL-1α is known as a proinflammatory cytokine and is generally produced by non-hematopoietic cells, such as epithelial cells, fibroblasts and stromal cells, in response to cell death, oxidative stresses, hormones or infection. 7 Although the biogenesis and secretion pathways of IL-1α remain poorly defined, the distinctive role of IL-1α in the inflammatory process has been extensively explored, especially in inflammatory and malignant human skin diseases. 8 Importantly, the Kanneganti group has shown that IL-1α produced by nonhematopoietic cells is essential for the development of neutrophilic inflammation in the footpad. They postulated that microbiota primes IL-1α expression in the non-hematopoietic compartment to promote autoimmunity because antibiotic treatment prevents the onset of skin disease in Ptpn6 spin mice. 6 However, it is not known how microbiota triggers IL-1α production in these cells because most innate signaling axes in sensing microbes, such as TLRs, NODs and interferons, are likely unrelated to inflammation in Ptpn6 spin mice. Moreover, it is important to determine whether the IL-1α-IL-1R axis has a self-activation or self-amplification behavior because IL-1R expression is necessary in radioresistant cells for disease progression. Although both myeloid and radioresistant cells require MyD88 for autoinflammation, it is not clear whether the MyD88-dependent IL-1R pathway in myeloid cells can be utilized in the IL-1α-producing nonhematopoietic cells.
The regulation of cell death signaling pathways has been implicated in the pathogenesis of inflammatory diseases. RIPK1 has been found in signaling downstream of many receptors to induce cell death via its kinase activity or to modulate inflammatory signaling and cell survival via its kinase-independent scaffold functions. RIPK1 is also critical for the regulation of Fas-associated death domain protein (FADD)-caspase-8-dependent apoptosis and RIPK3-mixed lineage kinase such as (MLKL)-dependent necroptosis. 9 Thus, the Kanneganti group demonstrated that RIPK1, but not 
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Figure 1 SHP-1 (PTPN6) prevents IL-1α-driving inflammatory skin diseases by inhibiting Syk-dependent MyD88 phosphorylation in IL-1R
signaling. In steady state, IL-1R in neutrophils cannot respond to IL-1α, which is produced by skin microbiota-stimulated non-hematopoietic cells, because SHP-1 inactivated SYK and stops the IL-1R signaling. When SHP-1 is deficient (me/me) or mutated (spin), the active SYK can phosphorylate MyD88 and then recruit RIPK1 and TAK1 to activate downstream signaling and promote the generation of proinflammatory cytokines. Thus, the defect of SHP-1 results in neutrophilic inflammation in skin. Gcsf, granulocyte colony-stimulating factor; IL-1α, interleukin-1α; IL-1R, IL-1 receptor; me, motheaten; MyD88, myeloid differentiation primary response gene 88; P, phosphorylation; PTPN6, protein tyrosine phosphatase nonreceptor type 6; RIPK1, receptor interacting protein kinase 1; SHP-1, SH2 domain-containing protein phosphatase; spin, spontaneous inflammation; SYK, spleen tyrosine kinase; TAK1, tumor growth factor-β activated kinase 1; Y, tyrosine. TNF, tumor necrosis factor. (Drawn by Mr Hsuan-Chao Lin, Graduate Institute of Immunology, National Taiwan University, Taiwan).
RIPK3, critically mediates IL-1α production by hematopoietic cells and then drives wound-induced tissue damage and inflammatory skin disease in Ptpn6 Spin mice using fetal liver chimera studies. 5 More recently, genetic evidence was provided to further confirm the role of RIPK1 scaffold function, but not RIPK1 kinase activity or RIPK3-MLKLdependent necroptosis, in the autoinflammation that is observed in Ptpn6 spin mice. Furthermore, TAK1 was shown to be involved with RIPK1-dependent inflammation and disease progression in Ptpn6 spin mice, which suggests a new target gene in IL-1R signaling. Because TAK1 is activated by Lys63-linked ubiquitin (K63-Ub) chains after IL-1 stimulation, 10 it would be interesting to clarify whether K63-Ub can interact with PIPK1 in IL-1R signaling.
A critical finding from their study is that Syk promotes MyD88 phosphorylation and provokes skin inflammation in Ptpn6 spin mice. It has been established that Syk is involved in many signaling pathways that are initiated from various surface receptors. Therefore, Syk has a key role in inflammatory responses induced by the activation and migration of myeloid cells. 11 Although Syk has been shown to associate with TNF receptor-associated factor-6 (TRAF-6) after IL-1 stimulation in nasal fibroblast lines, 12 their study is the first to demonstrate the involvement of Syk in IL-1R signaling in myeloid cells. However, it is not known how IL-1α treatment can activate Syk, and whether Src kinases and ITAM-containing adapters are required. 11 In addition, it remains to be clarified whether Syk-dependent MyD88 phosphorylation can occur in other MyD88-dependent signaling pathways. Han et al. illustrated that Syk, which is activated by CD11b integrin, can phosphorylate MyD88 in TLR signaling, but the phosphorylation site of MyD88 (Tyr227) is different from that in IL-1R signaling (Tyr180/278), as shown here. Another different feature from IL-1R signaling is that the Syk-induced MyD88 phosphorylation in TLR signaling recruits the E3 ligase Cbl-b to degrade MyD88 and then decrease the TLR response. 13 The different patterns of tyrosine phosphorylation of MyD88 that result in such opposite immune responses should be further investigated. In other studies, Syk has also been reported to modulate TLR signaling via mechanisms that are different from the regulation of posttranscriptional modification of MyD88 in myeloid cells. 14 In B cells, Syk activation triggered by TLR4 ligand is dependent on BCR. 15 Accordingly, Syk may be distinctly regulated in different MyD88-dependent signaling pathways and in different cell types, as suggested by the distinct roles of neutrophils and dendritic cells in motheaten mice. 4 In summary, the Kanneganti group has suggested several therapeutic strategies to treat skin autoinflammatory diseases, including IL-1α-neutralization approaches and therapies that target the RIPK1-TAK1 signaling axis, SYK and MyD88 phosphorylation. SYK inhibitors have been developed to treat autoimmune rheumatic diseases. 16 It seems feasible to apply these inhibitors in AIS therapy. However, approaches that target RIPK1 should be considered carefully because RIPK1 kinase activity is not required for disease progression. Furthermore, it may be beneficial to design a strategy to prevent MyD88 phosphorylation in IL-1R signaling. However, this strategy could likely be complicated due to various downstream effects that result from different MyD88 phosphorylation patterns. In addition to these molecules, phosphatidylinositol phosphate kinase type Ic (PIPKIc), which interacts with PTPN6, regulates neutrophil migration to inflammatory tissue and could be a potential target. 17 We hope that researchers will reveal more pathogenic mechanisms of AIS and then find a critical target to develop an effective therapy in the future.
